Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Drug-eluting Beads Transarterial Chemoembolization Combined With Apatinib and PD-1 Antibody for the Treatment of Intrahepatic Cholangiocarcinoma That Has Progressed After Standard First-line Chemotherapy

NCT04834674 is registered in ClinicalTrials.gov with Sichuan Cancer Hospital and Research Institute as lead sponsor.

NCT NCT04834674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04834674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Drug-eluting Beads Transarterial Chemoembolization Combined With Apatinib and PD-1 Antibody for the Treatment of Intrahepatic Cholangiocarcinoma That Has Progressed After Standard First-line Chemotherapy
Lead sponsor
Sichuan Cancer Hospital and Research Institute
Phase
Phase 2
Overall status
Completed
Start date
July 1, 2024
Completion date
April 5, 2026
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

apatinib, intrahepatic cholangiocarcinoma, pd-1 antibody, transarterial chemoembolization